Werycyguat jako innowacyjna strategia leczenia niewydolności serca
Keywords:
werycyguat, niewydolność serca, cykliczny guanozynomonofosforanSynopsis
Abstrakt:
Werycyguat jest nowym, bezpośrednim stymulatorem rozpuszczalnej cyklazy guanylowej. Działa w obrębie szlaku tlenek azotu – rozpuszczalna cyklaza guanylowa – cykliczny guanozynomonofosforan (cGMP). Lek ten prowadzi do podniesienia stężenia cGMP, które jest obniżone u pacjentów z niewydolnością serca. Zwiększenie stężenia cGMP przyczynia się do poprawy funkcji układu sercowo-naczyniowego. Werycyguat został zatwierdzony do stosowania w leczeniu niewydolności serca ze zmniejszoną frakcją wyrzutową, gdzie wykazuje korzystny wpływ na rokowanie pacjentów oraz zmniejsza ryzyko hospitalizacji i zgonu. Werycyguat jest obecnie stosowany jako istotny nowy filar postępowania terapeutycznego w leczeniu niewydolności serca, a jego odmienny, unikalny mechanizm działania czyni go cennym uzupełnieniem standardowej terapii. Z uwagi na rosnącą liczbę chorych pacjentów oraz ograniczenia dotychczasowych opcji terapeutycznych, werycyguat stanowi obiecującą perspektywę dla dalszego rozwoju zindywidualizowanego leczenia niewydolności serca.
Słowa kluczowe: werycyguat, niewydolność serca, cykliczny guanozynomonofosforan
Abstract:
Vericiguat is a novel, direct stimulator of soluble guanylate cyclase (sGC). It acts within the nitric oxide–soluble guanylate cyclase–cyclic guanosine monophosphate (cGMP) pathway. This drug increases cGMP levels, which are typically reduced in patients with heart failure. Elevated cGMP concentrations contribute to improved cardiovascular function. Vericiguat has been approved for the treatment of heart failure with reduced ejection fraction, where it demonstrates a beneficial effect on patient prognosis and reduces the risk of hospitalization and death. It is currently used as a key new pillar in the therapeutic management of heart failure, and its distinct, unique mechanism of action makes it a valuable complement to standard therapy. Given the growing number of affected patients and the limitations of existing treatment options, vericiguat offers a promising perspective for the further development of individualized heart failure therapy.
Keywords: vericiguat, heart failure, cyclic guanosine monophosphate
References
Braunwald E. Cardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and Opportunities. N Engl J Med. 1997;337(19):1360-1369. doi:10.1056/NEJM199711063371906
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272-3287. doi:10.1093/cvr/cvac013
James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1789-1858. doi:10.1016/S0140-6736(18)32279-7
Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. doi:10.1002/ejhf.2115
Roger VL. Epidemiology of Heart Failure. Circ Res. 2021;128(10):1421-1434. doi:10.1161/CIRCRESAHA.121.318172
Trujillo ME, Ayalasomayajula S, Blaustein RO, Gheyas F. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2023;16(12):2458-2466. doi:10.1111/cts.13677
Becker C, Boettcher M, Muenster U, Loewen S, Lobmeyer M, Mueck W. Results from in vitro and in vivo studies evaluating the bioavailability, effects of food, and administration as crushed tablet suspension on vericiguat pharmacokinetics. AAPS Open. 2022;8(1):16. doi:10.1186/s41120-022-00063-4
Rüdebusch J, Benkner A, Nath N, et al. Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling. Br J Pharmacol. 2022;179(11):2430-2442. doi:10.1111/bph.15333
Sandner P, Vakalopoulos A, Hahn MG, Stasch JP, Follmann M. Soluble guanylate cyclase stimulators and their potential use: a patent review. Expert Opin Ther Pat. 2021;31(3):203-222. doi:10.1080/13543776.2021.1866538
Sandner P, Follmann M, Becker-Pelster E, et al. Soluble GC stimulators and activators: Past, present and future. Br J Pharmacol. 2024;181(21):4130-4151. doi:10.1111/bph.15698
Kang Y, Liu R, Wu JX, Chen L. Structural insights into the mechanism of human soluble guanylate cyclase. Nature. 2019;574(7777):206-210. doi:10.1038/s41586-019-1584-6
Horst BG, Yokom AL, Rosenberg DJ, et al. Allosteric activation of the nitric oxide receptor soluble guanylate cyclase mapped by cryo-electron microscopy. eLife. 2019;8:e50634. doi:10.7554/eLife.50634
Adler J, Kuret A, Längst N, Lukowski R. Targets of cGMP/cGKI in Cardiac Myocytes. J Cardiovasc Pharmacol. 2020;75(6):494-507. doi:10.1097/FJC.0000000000000817
Breitenstein S, Roessig L, Sandner P, Lewis KS. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. Handb Exp Pharmacol. 2017;243:225-247. doi:10.1007/164_2016_100
Hulot JS, Trochu JN, Donal E, et al. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. Expert Opin Pharmacother. 2021;22(14):1847-1855. doi:10.1080/14656566.2021.1937121
Fritsch A, Meyer M, Blaustein RO, et al. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat. Clin Pharmacokinet. 2024;63(6):751-771. doi:10.1007/s40262-024-01384-1
Russo P, Vitiello L, Milani F, et al. New Therapeutics for Heart Failure Worsening: Focus on Vericiguat. J Clin Med. 2024;13(14):4209. doi:10.3390/jcm13144209
Chiles R, Al-Horani RA. Vericiguat: A New Hope for Heart Failure Patients. Cardiovasc Ther. 2022;2022:1554875. doi:10.1155/2022/1554875
Sahana U, Wehland M, Simonsen U, Schulz H, Grimm D. A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure. Int J Mol Sci. 2023;24(14):11826. doi:10.3390/ijms241411826
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
Rao VN, Diez J, Gustafsson F, et al. Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events. J Card Fail. 2023;29(3):389-402. doi:10.1016/j.cardfail.2022.10.431
Fritsch A, Meyer M, Blaustein RO, et al. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat. Clin Pharmacokinet. 2024;63(6):751-771. doi:10.1007/s40262-024-01384-1
Xia J, Hui N, Tian L, et al. Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF). Biomed Pharmacother. 2022;149:112894. doi:10.1016/j.biopha.2022.112894
Pieske B, Maggioni AP, Lam CSP, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119-1127. doi:10.1093/eurheartj/ehw593
Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150(4):707-715. doi:10.1016/j.ahj.2004.12.010
Cruz L, Ryan JJ. Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci. 2017;2(3):341-343. doi:10.1016/j.jacbts.2017.05.004
Chen C, Lv J, Liu C. Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA. Front Endocrinol. 2024;15. doi:10.3389/fendo.2024.1335531
Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-1893. doi:10.1056/NEJMoa1915928
Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382(20):1883-1893. doi:10.1056/NEJMoa1915928
Trujillo ME, Ayalasomayajula S, Blaustein RO, Gheyas F. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2023;16(12):2458-2466. doi:10.1111/cts.13677
Damman K, Valente MAE, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35(7):455-469. doi:10.1093/eurheartj/eht386
Voors AA, Mulder H, Reyes E, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. Eur J Heart Fail. 2021;23(8):1313-1321. doi:10.1002/ejhf.2221
Khan MS, Butler J, Young R, et al. Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial. JACC Heart Fail. 2024;12(10):1750-1759. doi:10.1016/j.jchf.2024.05.007
Kang C, Lamb YN. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction. Am J Cardiovasc Drugs Drugs Devices Interv. 2022;22(4):451-459. doi:10.1007/s40256-022-00538-5
Breitenstein S, Roessig L, Sandner P, Lewis KS. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. Handb Exp Pharmacol. 2017;243:225-247. doi:10.1007/164_2016_100
Li L, Zhang W, Lin F, et al. Synthesis and biological evaluation of pyrazolo[3,4-b]pyridine-3-yl pyrimidine derivatives as sGC stimulators for the treatment of pulmonary hypertension. Eur J Med Chem. 2019;173:107-116. doi:10.1016/j.ejmech.2019.04.014
Xia J, Hui N, Tian L, et al. Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF). Biomed Pharmacother. 2022;149:112894. doi:10.1016/j.biopha.2022.112894
Gheorghiade M, Greene SJ, Filippatos G, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. doi:10.1093/eurjhf/hfs093
Hashimoto T, Yoshitake T, Suenaga T, et al. Effectiveness of Vericiguat on right ventricle to pulmonary artery uncoupling associated with heart failure with reduced ejection fraction. Int J Cardiol. 2024;415:132441. doi:10.1016/j.ijcard.2024.132441
Elad B, Lee C, Baranowska J, et al. Vericiguat Experience in Durable Left Ventricular Assist Device Patients. Artif Organs. Published online March 31, 2025. doi:10.1111/aor.14971
Fritsch A, Meyer M, Blaustein RO, et al. Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat. Clin Pharmacokinet. 2024;63(6):751-771. doi:10.1007/s40262-024-01384-1
Rao VN, Diez J, Gustafsson F, et al. Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events. J Card Fail. 2023;29(3):389-402. doi:10.1016/j.cardfail.2022.10.431
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063
Chen C, Lv J, Liu C. Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA. Front Endocrinol. 2024;15. doi:10.3389/fendo.2024.1335531
Trujillo ME, Ayalasomayajula S, Blaustein RO, Gheyas F. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science. doi:10.1111/cts.13677
Published
August 24, 2025
Copyright (c) 2025 Mateusz Gołębiowski, Tymoteusz Borowski, Nina Jankowska, Maria Zimoń, Joanna Bogacz, Aleksandra Dziegciarz
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
